BioCardia's autologous bone marrow cell therapy demonstrated sustained improvements in exercise capacity and angina reduction over two years in patients with chronic myocardial ischemia who had exhausted standard interventions. The therapy showed no treatment-emergent major adverse cardiac events, with exercise tolerance gains of 179 seconds persisting through follow-up and angina episodes declining 82% at six months.
Key Points
- Exercise tolerance increased 179 seconds, sustained at two years
- Angina episodes reduced 82% at six months post-treatment
- No major adverse cardiac events through two-year follow-up
Longevity Analysis
Chronic myocardial ischemia represents a fundamental constraint on circulation and energy production—the systems that determine functional capacity and longevity. Patients enrolled in this trial had exhausted conventional options, placing them in a category where tissue regeneration becomes the primary mechanism available. The sustained nature of these improvements suggests the therapy may address underlying tissue function rather than providing temporary symptomatic relief. For patients with advanced ischemic disease, restoration of cardiac output and exercise tolerance directly improves quality of life and reduces the physiological stress burden that accelerates age-related decline. This approach represents a meaningful shift from managing symptoms toward recovering tissue capacity.
Original published by Longevity.Technology.